ClinicalTrials.gg
CompletedNCT02537899SATURNUpdated Mar 15, 2024

Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD

A Phase 4 interventional study of NeuroAiD in Spinal Cord Injury, sponsored by Moleac Pte Ltd.. Completed at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Moleac Pte Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2015, registered Aug 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

SATURN investigates the promising role of NeuroAiD in patients with spinal cord injury and will provide important information on the feasibility of conducting larger controlled trials.

Read the detailed description

SATURN is a prospective cohort study of patients with moderately-severe to severe spinal cord injury, defined as American Spinal Injury Association Impairment Scale A and B, who are treated with open-label NeuroAiD for 6 months in addition to standard care and followed for 24 months. Anonymized data will be prospectively collected at baseline and months 1, 3, 6, 12, 18, and 24 using a secured online system and will include information on demographics, main diagnostics, neurological and functional state, treatment compliance, concomitant therapies, and side effects, if any.

02

Conditions studied

  • Spinal Cord Injury
03

In context

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.

This study's enrollment of 30 is above the median of 24 across 1,634 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Moleac Pte Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18 to 65 years
  • Diagnosed with spinal cord injury between 3 days and 4 weeks
  • American Spinal Injury Association Impairment Scale A or B
  • for inclusion into the database is obtained

Exclusion criteria

Exclusion Criteria:

  • Non survivable injury
  • Multiple significant trauma (i.e. significant intracranial and extracranial injuries including limb fractures) that would limit observation of recovery from spinal cord injury
  • Other conditions that would limit clinical assessment of outcomes (e.g. dementia, demyelinating disease, disease, etc)
  • Refusal of treatment or to NeuroAiD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Treatment

    NeuroAiD

    Drug: NeuroAiD

Interventions

  • Also known as: MLC601, MLC901

06

What researchers measure

Primary outcomes

  1. Spinal cord injury severity based on American Spinal Injury Association Impairment Scale

    Time frame: 6 months

  2. Motor recovery based on American Spinal Injury Association Impairment Scale motor score

    Time frame: 6 months

  3. Number of patients experiencing adverse events

    Adverse events as individual events and according to organ system, severity, and relatedness

    Time frame: 6 months

Secondary outcomes

  1. Spinal cord injury severity based on American Spinal Injury Association Impairment Scale

    Time frame: 1, 3, 12, 18, 24 months

  2. Motor recovery based on American Spinal Injury Association Impairment Scale motor score

    Time frame: 1, 3, 12, 18, 24 months

  3. Sensory recovery based on American Spinal Injury Association Impairment Scale sensory score

    Time frame: 1, 3, 6, 12, 18, 24 months

  4. Functional state based on Spinal Cord Independence Measure

    Time frame: 1, 3, 6, 12, 18, 24 months

  5. Quality of life based on Short Form-8 Health Survey

    Time frame: 1, 3, 6, 12, 18, 24 months

07

Study locations

1 site
  • University Kebangsaan Malaysia Medical Centre
    Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur 56000, Malaysia
08

References and documents

Publications

  • Kumar R, Htwe O, Baharudin A, Rhani SA, Ibrahim K, Nanra JS, Gsangaya M, Harun H, Kandar K, Balan M, Peh S, Pokharkar Y, Ingole A, Hisam Ariffin M. Spinal cord injury - assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study - primary results of an exploratory study. J Spinal Cord Med. 2023 Jul;46(4):682-686. doi: 10.1080/10790268.2022.2067972. Epub 2022 May 23. PubMed 35604343 ↗
  • Kumar R, Htwe O, Baharudin A, Ariffin MH, Abdul Rhani S, Ibrahim K, Rustam A, Gan R. Spinal Cord Injury-Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury. JMIR Res Protoc. 2016 Dec 5;5(4):e230. doi: 10.2196/resprot.6275. PubMed 27919862 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Sep 2023, 101 months.

Of 19 phase 4 interventional studies under Spinal Cord Injuries, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 101 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2015
First posted
Sep 2, 2015
StartActual
Apr 2015
Primary completionActual
Sep 20, 2023
CompletionActual
Sep 20, 2023
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02537899
Lead sponsor
Moleac Pte Ltd.
Responsible party
Sponsor
First posted
Sep 2, 2015
Start date
Apr 2015
Primary completion
Sep 20, 2023
Completion
Sep 20, 2023
Last update
Mar 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neuroaid

Start the discussion